|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 38/13 | (2006.01) |
| A61K 38/26 | (2006.01) | ||
| A61P 9/10 | (2006.01) |
| (11) | Number of the document | 3370756 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16802132.7 |
| Date of filing the European patent application | 2016-11-04 | |
| (97) | Date of publication of the European application | 2018-09-12 |
| (45) | Date of publication and mention of the grant of the patent | 2020-04-08 |
| (46) | Date of publication of the claims translation | 2020-07-10 |
| (86) | Number | PCT/IB2016/001582 |
| Date | 2016-11-04 |
| (87) | Number | WO 2017/077378 |
| Date | 2017-05-11 |
| (30) | Number | Date | Country code |
| 20150100486 | 2015-11-06 | GR |
| (72) |
VOGIATZIS, George, GR
|
| (73) |
Genesis Pharma SA,
270 Kifissias Avenue, 15232 Athens,
GR
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kanrenoato ir eksenatido derinys |
| COMBINATION OF CANRENOATE AND EXENATIDE |
| Payment date | Validity (years) | Amount | |
| 2024-10-25 | 9 | 208.00 EUR |
| 2025-11-04 |